1
|
Dai J, Luo W, Hu F, Li S. In vitro inhibition of Pseudomonas aeruginosa PAO1 biofilm formation by DZ2002 through regulation of extracellular DNA and alginate production. Front Cell Infect Microbiol 2024; 13:1333773. [PMID: 38268790 PMCID: PMC10806038 DOI: 10.3389/fcimb.2023.1333773] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2023] [Accepted: 12/15/2023] [Indexed: 01/26/2024] Open
Abstract
Introduction Pseudomonas aeruginosa (P. aeruginosa) is a common pathogen associated with biofilm infections, which can lead to persistent infections. Therefore, there is an urgent need to develop new anti-biofilm drugs. DZ2002 is a reversible inhibitor that targets S-adenosylhomocysteine hydrolase and possesses anti-inflammatory and immune-regulatory activities. However, its anti-biofilm activity has not been reported yet. Methods and results Therefore, we investigated the effect of DZ2002 on P. aeruginosa PAO1 biofilm formation by crystal violet staining (CV), real-time quantitative polymerase chain reaction (RT-qPCR) and confocal laser scanning microscopy (CLSM). The results indicated that although DZ2002 didn't affect the growth of planktonic PAO1, it could significantly inhibit the formation of mature biofilms. During the inhibition of biofilm formation by DZ2002, there was a parallel decrease in the synthesis of alginate and the expression level of alginate genes, along with a weakening of swarming motility. However, these results were unrelated to the expression of lasI, lasR, rhII, rhIR. Additionally, we also found that after treatment with DZ2002, the biofilms and extracellular DNA content of PAO1 were significantly reduced. Molecular docking results further confirmed that DZ2002 had a strong binding affinity with the active site of S-adenosylhomocysteine hydrolase (SahH) of PAO1. Discussion In summary, our results indicated that DZ2002 may interact with SahH in PAO1, inhibiting the formation of mature biofilms by downregulating alginate synthesis, extracellular DNA production and swarming motility. These findings demonstrate the potential value of DZ2002 in treating biofilm infections associated with P. aeruginosa.
Collapse
Affiliation(s)
- Jiaze Dai
- Medical Laboratory Center, Affiliated Hospital of Guangdong Medical University, Zhan Jiang, Guang Dong, China
| | - Wenying Luo
- Medical Laboratory Center, Affiliated Hospital of Guangdong Medical University, Zhan Jiang, Guang Dong, China
| | - Fei Hu
- Medical Laboratory Center, Affiliated Hospital of Guangdong Medical University, Zhan Jiang, Guang Dong, China
| | - Si Li
- General Medicine, Clinical Medicine, Kangda College of Nanjing Medical University, LianYun Gang, Jiang Su, China
| |
Collapse
|
2
|
Fernández-Barat L, Vázquez Burgos N, Alcaraz V, Bueno-Freire L, López-Aladid R, Cabrera R, Gabarrús A, Palomeque A, Oscanoa P, Ceccato A, Motos A, Amaro R, Bernardi T, Provot C, Soler-Comas A, Muñoz L, Vila J, Torres A. The value of biofilm testing to guide antimicrobial stewardship in chronic respiratory diseases. Front Cell Infect Microbiol 2023; 13:1142274. [PMID: 37201119 PMCID: PMC10187140 DOI: 10.3389/fcimb.2023.1142274] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2023] [Accepted: 04/04/2023] [Indexed: 05/20/2023] Open
Abstract
Introduction Biofilm production is an important yet currently overlooked aspect of diagnostic microbiology that has implications for antimicrobial stewardship. In this study, we aimed to validate and identify additional applications of the BioFilm Ring Test® (BRT) for Pseudomonas aeruginosa (PA) isolates from patients with bronchiectasis (BE). Materials and methods Sputa were collected from BE patients who had at least one PA positive culture in the previous year. We processed the sputa to isolate both mucoid and non-mucoid PA, and determined their susceptibility pattern, mucA gene status, and presence of ciprofloxacin mutations in QRDR genes. The Biofilm production index (BPI) was obtained at 5 and 24 hours. Biofilms were imaged using Gram staining. Results We collected 69 PA isolates, including 33 mucoid and 36 non-mucoid. A BPI value below 14.75 at 5 hours predicted the mucoid PA phenotype with 64% sensitivity and 72% specificity. Conclusion Overall, our findings suggest that the fitness-cost associated with the mucoid phenotype or ciprofloxacin resistance is shown through a time-dependent BPI profile. The BRT has the potential to reveal biofilm features with clinical implications.
Collapse
Affiliation(s)
- Laia Fernández-Barat
- Cellex Laboratory, CibeRes (CB06/06/0028)-Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), School of Medicine, University of Barcelona, Barcelona, Spain
- Pneumology Service, Respiratory Institute, Hospital Clinic, Barcelona, Spain
- *Correspondence: Laia Fernández-Barat, ; Antoni Torres,
| | - Nil Vázquez Burgos
- Cellex Laboratory, CibeRes (CB06/06/0028)-Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), School of Medicine, University of Barcelona, Barcelona, Spain
- Pneumology Service, Respiratory Institute, Hospital Clinic, Barcelona, Spain
| | - Victoria Alcaraz
- Cellex Laboratory, CibeRes (CB06/06/0028)-Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), School of Medicine, University of Barcelona, Barcelona, Spain
- Pneumology Service, Respiratory Institute, Hospital Clinic, Barcelona, Spain
| | - Leticia Bueno-Freire
- Cellex Laboratory, CibeRes (CB06/06/0028)-Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), School of Medicine, University of Barcelona, Barcelona, Spain
- Pneumology Service, Respiratory Institute, Hospital Clinic, Barcelona, Spain
| | - Ruben López-Aladid
- Cellex Laboratory, CibeRes (CB06/06/0028)-Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), School of Medicine, University of Barcelona, Barcelona, Spain
- Pneumology Service, Respiratory Institute, Hospital Clinic, Barcelona, Spain
| | - Roberto Cabrera
- Cellex Laboratory, CibeRes (CB06/06/0028)-Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), School of Medicine, University of Barcelona, Barcelona, Spain
- Pneumology Service, Respiratory Institute, Hospital Clinic, Barcelona, Spain
| | - Albert Gabarrús
- Cellex Laboratory, CibeRes (CB06/06/0028)-Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), School of Medicine, University of Barcelona, Barcelona, Spain
- Pneumology Service, Respiratory Institute, Hospital Clinic, Barcelona, Spain
| | - Andrea Palomeque
- Cellex Laboratory, CibeRes (CB06/06/0028)-Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), School of Medicine, University of Barcelona, Barcelona, Spain
- Pneumology Service, Respiratory Institute, Hospital Clinic, Barcelona, Spain
| | - Patricia Oscanoa
- Cellex Laboratory, CibeRes (CB06/06/0028)-Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), School of Medicine, University of Barcelona, Barcelona, Spain
- Pneumology Service, Respiratory Institute, Hospital Clinic, Barcelona, Spain
| | - Adrian Ceccato
- Cellex Laboratory, CibeRes (CB06/06/0028)-Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), School of Medicine, University of Barcelona, Barcelona, Spain
- Pneumology Service, Respiratory Institute, Hospital Clinic, Barcelona, Spain
| | - Ana Motos
- Cellex Laboratory, CibeRes (CB06/06/0028)-Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), School of Medicine, University of Barcelona, Barcelona, Spain
- Pneumology Service, Respiratory Institute, Hospital Clinic, Barcelona, Spain
| | - Rosanel Amaro
- Cellex Laboratory, CibeRes (CB06/06/0028)-Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), School of Medicine, University of Barcelona, Barcelona, Spain
- Pneumology Service, Respiratory Institute, Hospital Clinic, Barcelona, Spain
| | - Thierry Bernardi
- BioFilm Pharma SAS, Lyon, France
- BioFilm Control SAS, Saint Beauzire, France
| | - Christian Provot
- BioFilm Pharma SAS, Lyon, France
- BioFilm Control SAS, Saint Beauzire, France
| | - Alba Soler-Comas
- Cellex Laboratory, CibeRes (CB06/06/0028)-Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), School of Medicine, University of Barcelona, Barcelona, Spain
- Pneumology Service, Respiratory Institute, Hospital Clinic, Barcelona, Spain
| | - Laura Muñoz
- Microbiology Service, Hospital Clinic, Barcelona, Spain
| | - Jordi Vila
- Microbiology Service, Hospital Clinic, Barcelona, Spain
| | - Antoni Torres
- Cellex Laboratory, CibeRes (CB06/06/0028)-Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), School of Medicine, University of Barcelona, Barcelona, Spain
- Pneumology Service, Respiratory Institute, Hospital Clinic, Barcelona, Spain
- *Correspondence: Laia Fernández-Barat, ; Antoni Torres,
| |
Collapse
|